Profile data is unavailable for this security.
About the company
Novacyt SA is a France-based company providing biotechnological solutions. The Company develops and markets solutions dedicated to the field of liquid-based cytology and molecular biology. The Company provides diagnostic products used in oncology, microbiology, haematology, and serology testing. The Company develops secure automated cytology named NovaPrep Processor System. Novacyt SA offers a solution of cytological sampling to help in the detection of precancerous and cancerous lesions. The Company creates bottles specifically dedicated to the optimization of cell collection. The Company’s range of products includes Bottle Gyn and No Gyn Bottle. Novacyt SA is present in France and internationally through a network of distributors.
- Revenue in EUR (TTM)320.86m
- Net income in EUR101.33m
- Incorporated2006
- Employees174.00
- LocationNovacyt SA13 avenue Morane SaulnierVELIZY VILLACOUBLAY 78140FranceFRA
- Phone+33 139465104
- Fax+33 130700532
- Websitehttps://novacyt.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spineguard SA | 4.80m | -2.16m | 33.42m | 14.00 | -- | 7.27 | -- | 6.96 | -0.0915 | -0.0915 | 0.2003 | 0.1547 | 0.481 | 1.95 | 6.88 | 369,522.30 | -21.62 | -32.72 | -41.70 | -59.03 | 73.32 | 79.19 | -44.95 | -40.24 | 1.92 | -1.06 | 0.5273 | -- | -28.95 | -5.23 | -296.13 | -- | -19.31 | -- |
| Pixium Vision SA | 2.64m | -10.90m | 41.96m | 28.00 | -- | 10.26 | -- | 15.88 | -0.2498 | -0.2498 | 0.0605 | 0.0697 | 0.1931 | -- | 502.73 | 94,351.43 | -79.68 | -51.14 | -113.78 | -58.40 | 100.00 | 86.35 | -412.56 | -553.85 | 2.71 | -12.46 | 0.49 | -- | 17.34 | -8.70 | 7.35 | -- | -47.73 | -- |
| Visiomed Group SA | 18.98m | -5.15m | 57.66m | 26.00 | -- | -- | -- | 3.04 | -0.2657 | -0.2657 | 1.02 | -0.1738 | 1.84 | 7.78 | 68.14 | 729,846.10 | -49.72 | -88.78 | -- | -214.56 | 9.41 | 33.62 | -27.04 | -130.93 | 0.4061 | -8.43 | -- | -- | 85.37 | 11.75 | 78.59 | -- | -17.42 | -- |
| Amplitude Surgical SA | 95.50m | -14.10m | 99.40m | 443.00 | -- | 1.68 | 40.99 | 1.04 | -0.2949 | -0.2949 | 2.00 | 1.23 | 0.3509 | 1.15 | 10.17 | 215,580.10 | -5.39 | -4.40 | -6.33 | -5.09 | 48.18 | 48.56 | -15.36 | -12.63 | 1.30 | -0.4317 | 0.7207 | -- | 8.17 | 3.40 | 0.6973 | -- | -12.07 | -- |
| Affluent Medical SAS | 0.00 | -14.88m | 101.54m | -- | -- | 1.98 | -- | -- | -0.8891 | -0.8891 | 0.00 | 2.83 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -5.77 | 0.2703 | -- | -- | -- | 13.68 | -- | -- | -- |
| Novacyt SA | 320.86m | 101.33m | 153.71m | 174.00 | 1.48 | 0.926 | 1.49 | 0.479 | 1.47 | 1.47 | 4.62 | 2.35 | 2.05 | 7.31 | 9.33 | 1,844,031.00 | 64.61 | 50.73 | 83.24 | 71.55 | 60.13 | 74.16 | 31.58 | 37.19 | 4.02 | 58.95 | 0.0205 | 0.00 | 2,317.20 | 112.09 | 3,973.15 | -- | 14.42 | -- |
| Carmat SA | 0.00 | -42.48m | 265.30m | 139.00 | -- | 7.86 | -- | -- | -3.45 | -3.45 | 0.00 | 2.20 | 0.00 | -- | -- | 0.00 | -58.90 | -71.39 | -69.94 | -85.87 | -- | -- | -- | -- | 5.52 | -14.28 | 0.5441 | -- | -- | -- | 13.33 | -- | 51.40 | -- |
| Bastide Le Confort Medical SA | 444.07m | 13.45m | 344.76m | 3.04k | 25.66 | 4.21 | 5.26 | 0.7764 | 1.83 | 1.83 | 60.36 | 11.14 | 0.8261 | 4.78 | 8.55 | 146,124.70 | 2.67 | 2.41 | 3.69 | 3.46 | 47.40 | 47.60 | 3.23 | 2.78 | 0.8196 | 3.91 | 0.8079 | 17.82 | 16.04 | 18.28 | 15.97 | 13.37 | 15.49 | 0.7577 |
| Lumibird SA | 156.40m | 12.64m | 462.82m | 870.00 | 29.01 | 2.71 | 19.68 | 2.96 | 0.71 | 0.71 | 8.27 | 7.61 | 0.5148 | 1.44 | 5.22 | 186,410.00 | 4.16 | 3.95 | 4.98 | 5.04 | 60.13 | 59.79 | 8.08 | 6.72 | 2.31 | 11.44 | 0.3456 | 0.00 | 14.46 | 15.32 | -36.08 | 21.54 | 29.37 | -- |
Data as of Jan 27 2022. Currency figures normalised to Novacyt SA's reporting currency: Euro EUR
5.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Investment Management (UK) Ltd.as of 12 Mar 2021 | 1.99m | 2.81% |
| J.O. Hambro Capital Management Ltd.as of 31 Dec 2021 | 1.06m | 1.49% |
| American Century Investment Management, Inc.as of 06 Jan 2022 | 204.55k | 0.29% |
| Goldman Sachs Asset Management LPas of 28 Feb 2021 | 122.07k | 0.17% |
| Lyxor International Asset Management SASas of 05 Jan 2022 | 98.48k | 0.14% |
| SSgA Funds Management, Inc.as of 06 Jan 2022 | 75.90k | 0.11% |
| FINEXIS SAas of 30 Jun 2020 | 61.23k | 0.09% |
| Quoniam Asset Management GmbHas of 31 Mar 2021 | 24.66k | 0.04% |
| Octopus Investments Ltd.as of 31 Dec 2021 | 9.30k | 0.01% |
| Inversis Gesti�n SGIIC SAas of 30 Sep 2021 | 4.89k | 0.01% |
More ▼
Data from 31 Dec 2020 - 19 Jan 2022Source: FactSet Research Systems Inc.
